1
|
Modoni S, Frangos S, Iakovou I, Boero M, Mansi L. Theragnostics before we found its name. THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING : OFFICIAL PUBLICATION OF THE ITALIAN ASSOCIATION OF NUCLEAR MEDICINE (AIMN) [AND] THE INTERNATIONAL ASSOCIATION OF RADIOPHARMACOLOGY (IAR), [AND] SECTION OF THE SOCIETY OF... 2021; 65:299-305. [PMID: 35133096 DOI: 10.23736/s1824-4785.21.03410-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Theragnostics embraces "gnosis" and "prognosis" and concerns a treatment strategy which combines diagnostics with therapeutics. The birth of what we call today theragnostics can be traced in 1936, with the proposal of radioiodine, the first radiopharmaceutical approved in 1951 by FDA, in USA, as 131I sodium iodide. In 1957, 89Sr was also approved as first therapeutic radiotracer for skeletal metastases, followed in the subsequent years by 186Rh, 153Sm and, more recently, 223Ra, the first alpha emitter clinically utilized, allowing curative results and not only a palliative effect. Proposed in first eighties as [131I] Metaiodobenzylguanidine (MIBG), the theragnostic couple 123I/131I MIBG is still used in neural crest tumors, while, starting from partially unsatisfactory results in 70's, models based on antibodies for radioimmunoscintigraphy/radioimmunotherapy have been subsequently upgraded thanks to the introduction of monoclonal antibodies and other significant biological and technical improvements. The "Theragnostics called with this name" can be dated to early 90's with the first proposal of the somatostatin model, actually widely operating in neuroendocrine tumors with radio-chelates usable for diagnosis and therapy. Since then, many investigators are working on new theragnostics agents, also outside of the nuclear medicine, based on peptides, antibodies and other tools to find new models applicable in the clinical practice. The fast growth is stimulated by the interest of big pharma. Theragnostic concepts are the roots of nuclear medicine and new great goals are soon to be achieved in the direction of an increasing precision and tailored medicine.
Collapse
Affiliation(s)
- Sergio Modoni
- Department of Nuclear Medicine, Foggia University Hospital, Foggia, Italy -
| | - Savvas Frangos
- Department of Nuclear Medicine, Clinic of Thyroid Cancer, Bank of Cyprus Oncology Center, Nicosia, Cyprus
| | - Ioannis Iakovou
- Medical School, Department of Academic Nuclear Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Michele Boero
- Department of Nuclear Medicine, ARNAS G. Brotzu, Cagliari, Italy
| | - Luigi Mansi
- Interuniversity Research Center for Sustainability (CIRPS), Rome, Italy
| |
Collapse
|
2
|
Murray I, Du Y. Systemic Radiotherapy of Bone Metastases With Radionuclides. Clin Oncol (R Coll Radiol) 2020; 33:98-105. [PMID: 33353771 DOI: 10.1016/j.clon.2020.11.028] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Revised: 11/23/2020] [Accepted: 11/30/2020] [Indexed: 11/30/2022]
Abstract
Treatments of bone metastases using radionuclides are now well established in oncology. It is also a field that continues to develop. This article reviews the evidence base that led to the approval of strontium-89 and samarium-153 ethylenediaminetetramethylene phophanate (EDTMP) for the palliation of pain from bone metastases, as well as the evidence for the use of radium-223 in metastatic castrate-resistant prostate cancer. Efforts to optimise treatments and improve response rates, either by safely increasing the radiation dose to bone metastases or by combining treatment with non-radiation-based therapies, are discussed. In addition, the development of both alpha- and beta-particle-emitting radiopharmaceuticals designed to target prostate-specific membrane antigen are reviewed.
Collapse
Affiliation(s)
- I Murray
- Joint Department of Physics, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK.
| | - Y Du
- Nuclear Medicine Department, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
| |
Collapse
|
3
|
Owaki Y, Inoue K, Narita H, Tsuda K, Fukushi M. Characteristic X-ray imaging for palliative therapy using strontium-89 chloride: understanding the mechanism of nuclear medicine imaging of strontium-89 chloride. Radiol Phys Technol 2017; 10:227-233. [PMID: 28054241 DOI: 10.1007/s12194-016-0388-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2016] [Revised: 12/21/2016] [Accepted: 12/26/2016] [Indexed: 12/01/2022]
Abstract
Strontium-89 (Sr-89) chloride is a targeted palliative therapy used for painful bone metastasis in which repeated doses can be administered, and its usefulness has been reported in the case of bone metastasis of various primary tumors. However, the effectiveness of the pain relief treatment is only described using a subjective index such as the visual analog scale, which lacks objectivity. Although various attempts at quantifying the effectiveness of Sr-89 chloride therapy have been reported using nuclear medicine imaging for energy peaks around 70-80 keV, the principle of Sr-89 chloride imaging has not been explained. In this study, the principle of nuclear medicine imaging for Sr-89 chloride was evaluated using a fundamental study. Additionally, the optimal collimator for acquiring Sr-89 chloride image data was evaluated. Based on the results, the principle of nuclear medicine imaging for Sr-89 chloride could be explained: the energy peaks were characteristic X-rays produced by interactions between gamma rays (514 keV) emitted from Sr-85, which is included during the manufacturing process of the Sr-89 chloride solution, and the lead collimator used in the imaging. The optimal collimator for generating characteristic X-rays efficiently was identified as a middle-to-high energy collimator.
Collapse
Affiliation(s)
- Yoshiki Owaki
- Department of Radiological Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University, Tokyo, 116-8551, Japan.,Office of Radiation Technology, Keio University Hospital, Tokyo, 160-0016, Japan
| | - Kazumasa Inoue
- Department of Radiological Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University, Tokyo, 116-8551, Japan.
| | - Hiroto Narita
- Department of Radiology, The Jikei University Hospital, Tokyo, 105-8471, Japan
| | - Keisuke Tsuda
- Department of Radiological Technology, Tsukuba International University, Tsukuba, Ibaraki, 300-0051, Japan
| | - Masahiro Fukushi
- Department of Radiological Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University, Tokyo, 116-8551, Japan
| |
Collapse
|
4
|
A dosimetric study of Beta induced bremsstrahlung in bone. Appl Radiat Isot 2014; 94:282-293. [DOI: 10.1016/j.apradiso.2014.08.016] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2012] [Revised: 07/28/2014] [Accepted: 08/26/2014] [Indexed: 11/19/2022]
|
5
|
Technical Considerations of Phosphorous-32 Bremsstrahlung SPECT Imaging after Radioembolization of Hepatic Tumors: A Clinical Assessment with a Review of Imaging Parameters. Radiol Res Pract 2014; 2014:407158. [PMID: 24800073 PMCID: PMC3985385 DOI: 10.1155/2014/407158] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2013] [Revised: 02/15/2014] [Accepted: 02/19/2014] [Indexed: 12/12/2022] Open
Abstract
Background. Bremsstrahlung (BS) imaging during radioembolization (RE) confirms the deposition of radiotracer in hepatic/extrahepatic tumors. The aim of this study is to demonstrate (32)P images and to optimize the imaging parameters. Materials and Methods. Thirty-nine patients with variable types of hepatic tumors, treated with the intra-arterial injection of (32)P, were included. All patients underwent BS SPECT imaging 24-72 h after tracer administration, using low energy high resolution (LEHR) (18 patients) or medium energy general purpose (MEGP) (21 patients) collimators. A grading scale from 1 to 4 was used to express the compatibility of the (32)P images with those obtained from CT/MRI. Results. Although the image quality obtained with the MEGP collimator was visually and quantitatively better than with the LEHR (76% concordance score versus 71%, resp.), there was no statistically significant difference between them. Conclusion. The MEGP collimator is the first choice for BS SPECT imaging. However, if the collimator change is time consuming (as in a busy center) or an MEGP collimator is not available, the LEHR collimator could be practical with acceptable images, especially in a SPECT study. In addition, BS imaging is a useful method to confirm the proper distribution of radiotherapeutic agents and has good correlation with anatomical findings.
Collapse
|
6
|
Ota S, Uno M, Kato M, Ishiguro M, Natsume T, Kikukawa K, Tadokoro M, Ichihara T, Toyama H. 89Sr bremsstrahlung single photon emission computed tomography using a gamma camera for bone metastases. Ann Nucl Med 2013; 28:112-9. [DOI: 10.1007/s12149-013-0788-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2013] [Accepted: 11/03/2013] [Indexed: 10/26/2022]
|
7
|
Abstract
In the nuclear medicine, beta nuclides are released during the treatment. This beta interacts with bone and muscle and produces external Bremsstrahlung (EB) radiation. Present work formulated a new method to evaluate the EB spectrum and hence the Bremsstrahlung dose of therapeutic beta nuclides (Lu-177, Sr-90, Sm-153, I-153, Cs-137, Au-201, Dy-165, Mo-99, Sr-89, Fe-59, P-32, Ho-166, Sr-92, Re-188, Y-90, Pr-147, Co-60, K-42) in bone and muscle. The Bremsstrahlung yields of these beta nuclides are also estimated. Bremsstrahlung production is higher in bone than that of muscle. Presented data provides a quick and convenient reference for radiation protection and it can be quickly employed to give a first pass dose estimate prior to a more detailed experimental study.
Collapse
Affiliation(s)
- H C Manjunatha
- Department of Physics, Government College for Women, Kolar, Karnataka, India
| |
Collapse
|
8
|
Yoshimura M, Uchida K, Okamoto J. [Strontium-89 imaging with bremsstrahlung in patients with metastatic bone cancer: imaging parameters and the clinical significancy]. Nihon Hoshasen Gijutsu Gakkai Zasshi 2013; 69:289-295. [PMID: 23514858 DOI: 10.6009/jjrt.2013_jsrt_69.3.289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Affiliation(s)
- Mana Yoshimura
- Department of Radiology, Tokyo Medical University, Japan
| | | | | |
Collapse
|
9
|
Sideras PA, Stavraka A, Gouliamos A, Limouris GS. Radionuclide therapy of painful bone metastases--a comparative study between consecutive radionuclide infusions, combination with chemotherapy, and radionuclide infusions alone: an in vivo comparison of their effectiveness. Am J Hosp Palliat Care 2012; 30:745-51. [PMID: 23264663 DOI: 10.1177/1049909112469719] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Radionuclides have been long used for the palliation of skeletal-related metastatic pain. They are almost invariably used as the last resource for pain palliation. Their use as single agents with dose escalations, in combination with biphosphonates or chemotherapy is well known in the peer-reviewed literature; however, little is known about the combination between different agents. In our study, we used consecutive administration of 2 different radionuclides such as (186)Re-1,1-hydroxyethylidenediphosphonate ((186)Re-HEDP) and (89)Strontium Chloride ((89)Sr-Cl) separated by adequate period of time to allow bone marrow recovery in patients with high chance of bone pain relapse and compared it with (89)Sr-Cl and chemotherapy group and (186)Re-HEDP with bisphosphonates. The end result was that treatment with consecutive radionuclides was much more effective and safe than the other 2 groups.
Collapse
|
10
|
Narita H, Hirase K, Uchiyama M, Fukushi M. New knowledge about the bremsstrahlung image of strontium-89 with the scintillation camera. Ann Nucl Med 2012; 26:603-7. [PMID: 22767009 DOI: 10.1007/s12149-012-0615-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2011] [Accepted: 03/01/2012] [Indexed: 10/28/2022]
Abstract
OBJECTIVE Strontium-89 ((89)Sr) chloride has been used to treat metastases in bone. A method to visualize the distribution of (89)Sr chloride with a scintillation camera was developed in 1996. Studies using bremsstrahlung imaging have shown that (89)Sr accumulates in bone and that the bremsstrahlung generated from biological tissue surrounding bone does not exceed 30 keV. However, it was not clear how low-energy bremsstrahlung from bone can produce peak energy levels of around 75 keV. We speculate that a different (unidentified) factor is involved. METHODS The energy spectrum of an (89)Sr source was acquired with a scintillation camera with or without a low-to-medium-energy general-purpose collimator. The energy window was set at 20-650 keV for 4 windows. A 50-mm thick acrylic block was placed between the scintillation camera and the (89)Sr source to exclude the effects of bremsstrahlung. The energy spectrum of (89)Sr covered with lead was acquired using the scintillation camera without a collimator. RESULTS With the collimator the energy spectrum curve was similar to that without the 50 mm of acrylic. The energy spectrum curve showed peaks at about 75, 170, and 520 keV. Without the collimator the energy spectrum showed a similar curve but no peak at 75 keV peak. The curve was similar to that obtained with the scintillation camera and the collimator; however, the curve obtained when the (89)Sr source had been placed in a lead container was similar to that obtained when the source was unshielded, and the collimator was not attached to the scintillation camera. CONCLUSION If bremsstrahlung of (89)Sr produces an image, a low-energy spectrum region should decrease when acrylic is placed between the (89)Sr source and the scintillation camera. However, similar curves were obtained both with the acrylic in place and without the acrylic. Therefore, we believe that the radiation detected by the scintillation camera was not bremsstrahlung due to the beta rays of (89)Sr. Most (89)Sr preparations are contaminated by (85)Sr, and most of the gamma ray energy of (85)Sr is 514 keV. The scintillation camera detected the characteristic X-ray energy of about 75 keV from the materials of the collimator (lead and others) through interaction with the gamma rays of (85)Sr.
Collapse
Affiliation(s)
- Hiroto Narita
- Department of Radiology, The Jikei University School of Medicine Hospital, 3-19-18 Nishishimbashi, Minato-ku, Tokyo, 105-8471, Japan.
| | | | | | | |
Collapse
|
11
|
Manjunatha H, Rudraswamy B. External bremsstrahlung spectra of the 90Sr source in some lead compounds measured using NaI detector. RADIAT MEAS 2012. [DOI: 10.1016/j.radmeas.2011.10.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
12
|
Yamada K, Yoshimura M, Kaise H, Ogata A, Ueda N, Tokuuye K, Kohno N. Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases. Exp Ther Med 2011; 3:226-230. [PMID: 22969873 DOI: 10.3892/etm.2011.405] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2011] [Accepted: 11/28/2011] [Indexed: 11/05/2022] Open
Abstract
Our aim in this study was to examine the safety and efficacy of the concurrent use of the radiopharmaceutical strontium-89 (Sr-89) chloride with zoledronic acid in standard anticancer therapy for breast cancer patients with painful multifocal bone metastases. The study comprised 16 breast cancer patients with painful multifocal bone metastases detected by bone scintigraphy, computed tomography or magnetic resonance imaging. All patients were treated with Sr-89 and zoledronic acid concurrently between March 2007 and February 2011 as part of a standard therapeutic regimen comprising chemotherapy, endocrine therapy, molecular targeting therapy and targeted radiotherapy. Sr-89 was administered intravenously at 2 MBq/kg to a maximum of 141 MBq per person. Safety was evaluated according to myelotoxicity as measured by the Common Terminology Criteria for Adverse Events (v3.0). To assess treatment efficacy, we monitored changes in analgesic drug dosages. Furthermore, bremsstrahlung imaging after the administration of Sr-89 was utilized to examine the relationship between the accumulation of Sr-89 in metastatic sites and treatment efficacy. Based on the results, a total of 14 out of 16 patients (88%) reported bone pain relief, indicating a high efficacy of Sr-89 combined with zoledronic acid. In responsive cases, a strong uptake of Sr-89 was observed on bremsstrahlung imaging at the same sites indicated by (99m)Tc bone scintigraphy. Moreover, severe myelosuppression (> grade 3) was not observed, and adverse events were tolerable. In conclusion, the use of Sr-89 with zoledronic acid in breast cancer patients with painful bone metastases was safe and effective when administered concurrently with other standard therapies. In the future, the treatment with Sr-89 at the early stage should be considered, and a large-scale clinical study should be conducted.
Collapse
Affiliation(s)
- Kimito Yamada
- Department of Breast Oncology, Tokyo Medical University Hospital
| | | | | | | | | | | | | |
Collapse
|
13
|
|
14
|
Manjunatha H, Rudraswamy B. Exposure of bremsstrahlung from beta-emitting therapeutic radionuclides. RADIAT MEAS 2009. [DOI: 10.1016/j.radmeas.2009.01.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
15
|
|
16
|
|
17
|
Theoretical data of external Bremsstrahlung radiation cross-section of bone. Appl Radiat Isot 2007; 65:397-400. [PMID: 17113303 DOI: 10.1016/j.apradiso.2006.10.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2006] [Revised: 05/17/2006] [Accepted: 10/01/2006] [Indexed: 11/26/2022]
Abstract
Theoretical data of external Bremsstrahlung (EB) radiation cross section of bone is estimated using tabulated results of EB cross section given for various elements at various photon and electron energies. This data may be useful in the analysis of Bremsstrahlung imaging which is the technique applied in medical therapy.
Collapse
|
18
|
Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 2006; 39:35-41. [PMID: 16434248 DOI: 10.1016/j.bone.2005.12.004] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2005] [Revised: 10/22/2005] [Accepted: 12/04/2005] [Indexed: 12/21/2022]
Abstract
PURPOSE We evaluated the pain response and daily discomfort in patients with painful bone metastases treated by merging 89Sr-chloride and zoledronic acid. The results were compared with those of patients who received 89Sr-chloride or zoledronic acid separately. METHODS 25 patients (12 women; mean age 65+/-13 years) chronically treated with zoledronic acid underwent bone pain palliation with 150 MBq of 89Sr-chloride at least 6 months later that bisphoshonate therapy started (group A). 13 patients (6 women; mean age 70+/-12 years) received 89Sr-chloride alone (group B) and 11 patients (5 women; mean age 69+/-12 years) were chronically treated and continued to receive only zoledronic acid therapy (group C), both constituted the control groups. Patients kept a daily pain diary assessing both their discomfort and the pain of specific sites by using a visual analog scale (VAS), rating from 0 (no d iscomfort-no pain) to 10 (worst discomfort-pain). These diaries were reviewed weekly for 2 months and three different physicians rated the pain response on a scale of -2 (considerable deterioration) to +2 (considerable improvement). RESULTS Baseline characteristics were similar in the three groups. The reduction of total discomfort and of bone pain in the group A was significantly greater as compared to group B (P<0.01) and group C (P<0.01). During the monitored period, a significant improvement of clinical conditions was observed in the group A, varying the rate from -1 to 1 as compared to both groups B and C in which the rate changed from -1 to 0. CONCLUSION Our findings indicate that combined therapy of 89Sr-chloride and zoledronic acid in patients with painful bone metastases is more effective in treating pain and improving clinical conditions than 89Sr-chloride or zoledronic acid used separately.
Collapse
Affiliation(s)
- Giovanni Storto
- Institute of Biostructures and Bioimages, National Council of Research, Naples, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Sun SS, Tsai SC, Hsieh JF, Lee JK, Kao CH. Discrepancy between clinical symptoms and Tc-99m MDP bone scan findings before and after strontium-89 therapy for metastatic bone pain of prostate carcinoma. Clin Nucl Med 2001; 26:167-9. [PMID: 11201488 DOI: 10.1097/00003072-200102000-00026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- S S Sun
- Department of Nuclear Medicine, China Medical College Hospital, Taichung, Taiwan
| | | | | | | | | |
Collapse
|